Pilulka Lékárny Past Earnings Performance

Past criteria checks 0/6

Pilulka Lékárny's earnings have been declining at an average annual rate of -169.4%, while the Consumer Retailing industry saw earnings growing at 8.7% annually. Revenues have been declining at an average rate of 12.9% per year.

Key information

-169.4%

Earnings growth rate

-150.9%

EPS growth rate

Consumer Retailing Industry Growth	12.4%
Revenue growth rate	-12.9%
Return on equity	-572.8%
Net Margin	-8.2%
Last Earnings Update	31 Dec 2023

Recent past performance updates

No updates

Recent updates

Pilulka Lékárny (SEP:PINK) Is Making Moderate Use Of Debt

Jun 12

Revenue & Expenses Breakdown

How Pilulka Lékárny makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SEP:PINK Revenue, expenses and earnings (CZK Millions)
Date	Revenue	Earnings	G+A Expenses
31 Dec 23	2,132	-175	364
31 Dec 22	2,447	-65	400
31 Dec 21	2,380	-25	0

Quality Earnings: PINK is currently unprofitable.

Growing Profit Margin: PINK is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PINK's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PINK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PINK is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Retailing industry (0.5%).

Return on Equity

High ROE: PINK has a negative Return on Equity (-572.75%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 03:57
End of Day Share Price	2025/01/02 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pilulka Lékárny a.s. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	Wood & Company